Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Gene activity plays key role in immune cell production, study shows

As people age or become ill, their immune systems can become exhausted and less capable of fighting off viruses such as the flu or COVID-19.

27 Jan 2024

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

24 Jan 2024

Unintentional weight loss linked to increased risk of cancer diagnosis

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

Decoding blood cancer secrets to optimize CAR T therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR T can be used as an earlier treatment option.

17 Jan 2024

UTEP researchers unveil promising new weapon against leukemia and lymphoma

Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy.

11 Jan 2024

Research discovers fibronectin's role in BRAF-mutant thyroid cancer resistance

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene -; a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer.

10 Jan 2024

Carvedilol improves heart health marker in childhood cancer survivors

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children's Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

9 Jan 2024

Fruit fly research solves human disease and fuels new cancer immunotherapy approach

Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency.

5 Jan 2024

Spicing up the fight: Saffron's powerful impact on prostate cancer revealed

Saffron-treated prostate cancer (PCa) cells.

3 Jan 2024

$Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL$

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

28 Dec 2023

Spatial profiling predicts recurrence of Hodgkin lymphoma after bone marrow transplant

Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.

22 Dec 2023

Low-magnification narrow-band imaging takes gastric cancer screening to the next level

Helicobacter pylori infection is recognized as a significant risk factor for gastric cancer. Hence regular screening for early detection is particularly crucial in regions with a high prevalence.

21 Dec 2023

Brazilian review explores emerging therapies for advanced Hodgkin lymphoma

A new review paper was published in Oncotarget's Volume 14 on December 12, 2023, entitled, "Current perspectives on the management of refractory or relapsed classic Hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability."

20 Dec 2023

Study reveals cytoglobin's pivotal role in cilia movement and organ positioning during development

Study reveals that cytoglobin (cygb2) plays a crucial role in regulating cilia motility and organ laterality during development, highlighting its importance in NO signaling and cilia function.

19 Dec 2023

Embryonic immune sensor could key to creating patient-derived blood stem cells

A microbial sensor that helps identify and fight bacterial infections also plays a key role in the development of blood stem cells, valuable new insight in the effort to create patient-derived blood stem cells that could eliminate the need for bone marrow transplants.

19 Dec 2023

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPα) for cancer immunotherapy.

19 Dec 2023

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

Researchers assessed mortality trends in the leading cancers from 2002 to 2019 across 314 districts in England using high-resolution spatiotemporal analysis.

14 Dec 2023

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers performed a molecular analysis of neuroendocrine neoplasm (NEN) patient-derived tumor organoids (PDTOs) and their parental neoplasms.

13 Dec 2023

Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

12 Dec 2023

Lymphoma News and Research

Further Reading

Gene activity plays key role in immune cell production, study shows

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

Unintentional weight loss linked to increased risk of cancer diagnosis

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Decoding blood cancer secrets to optimize CAR T therapy

UTEP researchers unveil promising new weapon against leukemia and lymphoma

Research discovers fibronectin's role in BRAF-mutant thyroid cancer resistance

Carvedilol improves heart health marker in childhood cancer survivors

Fruit fly research solves human disease and fuels new cancer immunotherapy approach

Spicing up the fight: Saffron's powerful impact on prostate cancer revealed

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Spatial profiling predicts recurrence of Hodgkin lymphoma after bone marrow transplant

Low-magnification narrow-band imaging takes gastric cancer screening to the next level

Brazilian review explores emerging therapies for advanced Hodgkin lymphoma

Study reveals cytoglobin's pivotal role in cilia movement and organ positioning during development

Embryonic immune sensor could key to creating patient-derived blood stem cells

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers find powerful combo weapon against aggressive lymphoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News